Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : WR's Momentum Trades -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (7903)	7/20/2000 11:39:03 AM
From: Wayne Rumball	Read Replies (1) \| Respond to of 11130

Got APVAF @ .93 for a bounce

To: Wayne Rumball who wrote (7903)	7/20/2000 11:51:13 AM
From: StocksDATsoar	Read Replies (1) \| Respond to of 11130

PUT THIS ON YOUR SCAN...WOW! Applies to -- ZKEM Xechem International, Inc. Announces More Patents Xechem International, Inc. Announces More Patents NEW BRUNSWICK, N.J., Jul 18, 2000 (BUSINESS WIRE) -- Xechem International, Inc. (OTC BB ZKEM) announced at its annual meeting held July 11, 2000 that it had received 7 new U.S. and 2 international patents during the past year, 7 of which are related to the field of the anticancer drug Paclitaxel and its second generation Paclitaxel analogs and two for diagnostic microbiological HEXOID(TM) plates. In addition, there are currently 30 international patents pending, with more on the way during the coming year. According to Dr. Ramesh Pandey, President & CEO "our Company is on the verge of exciting new ventures, and we expect to see a significant increase in activity in both the submission of our ANDA application for Paclitaxel in the United States before the end of this year, and the beginning of a world wide distribution of some of our nutraceutical products starting out in Southeast Asia and China in the next few months." Xechem International of New Brunswick, NJ, with subsidiary companies in USA, India and joint venture partners in both Hong Kong and Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche, generic, difficult to replicate anticancer, antiviral (including Human Immuno-deficiency Virus, HIV) and antifungal compounds. The Company also screens extracts and pure compounds from China, India and Indonesia for their therapeutic use. XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products as GinkgoOnce(R), GinsengOnce(R), GarlicOnce(R), Gugulon(TM), and Co-Enzyme Q-10 and numerous products which are under development. This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements. CONTACT: Xechem International, Inc., New Brunswick Dr. Ramesh C. Pandey President and Chief Executive Officer 732/247-3300 URL: businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2000 Business Wire. All rights reserved. Distributed via COMTEX. -0- KEYWORD: NEW JERSEY INDUSTRY KEYWORD: ALTERNATIVE MEDICINE MEDICAL PHARMACEUTICAL